Catalyst Pharmaceuticals, Inc. · NASDAQ:CPRX
Catalyst Pharmaceuticals — Investor Presentation (January 2024)
26 slides from Catalyst Pharmaceuticals's investor presentation, Jan 8, 2024
Slide 1: Dedicated to Making a Meaningful Difference in the Lives of Patients
NASDAQ: CPRX Dedicated to Making a Meaningful Difference in the Lives of Patients Suffering from Rare and Difficult to Treat Diseases January 2024 Exhibit 99.1
Slide 2: Safe Harbor
Safe Harbor This presentation contains forward-looking statements that are subject to a number of risks and uncertainties, many of which are outside our control. All statements regarding our strategy, future operations, financial position, estimated revenues or losses, projected costs, prospects, pl
Slide 3: A Differentiated Growth Rare Disease Company
Catalyst Pharmaceuticals Commercial Excellence Strategic Portfolio Expansion Highly Qualified Leadership Team Strong Financial Position Decades of combined industry experience, with extensive expertise spanning neurology, rare disease, and new product launches Demonstrated success acquiring and inte
Slide 4: Growing Revenues with a Diversified Portfolio
Growing Revenues with a Diversified Portfolio Neuromuscular FIRDAPSE® - rare neuromuscular disease AGAMREE® - rare muscular dystrophy disease Epilepsy FYCOMPA® - epileptic seizures Proprietary Portfolio Epilepsy Neuromuscular Product Franchises Focus on Rare Neurological and Epileptic Disorders Prov
Slide 5: Neuromuscular Franchise
Neuromuscular Franchise @ Catalyst
Slide 6: FIRDAPSE: Proprietary Flagship Product
FIRDAPSE: Proprietary Flagship Product FIRDAPSE® (amifampridine) Tablets 10mg Flagship product; approved in the U.S. in November 2018 Product launched - Q1 2019 Approved in people ≥6 years of age Orphan Drug Exclusivity through 2025 Strong intellectual property estate enhances durability IP protecti
Slide 7: Lambert Eaton Myasthenic Syndrome (LEMS)
Lambert Eaton Myasthenic Syndrome (LEMS) A Rare Neuromuscular Autoimmune Disease Affects Nerve-Muscle Communication May cause: Weakening of upper arms and shoulders muscles Severe, debilitating, and progressive weakness in the upper legs and hips Life-threatening weakness in respiratory muscles Most
Slide 8: FIRDAPSE: U.S. LEMS Market Opportunity
FIRDAPSE: U.S. LEMS Market Opportunity Significant Unmet Need >1,100 LEMS-diagnosed patients ever treated with FIRDAPSE 2 ˜800 LEMS patients diagnosed but not yet treated with FIRDAPSE > 2,900 LEMS undiagnosed patients Making A Meaningful Difference In Patients’ Lives Affects ˜3,600 - 5,600 people (
Slide 9: Many SCLC LEMS patients are undiagnosed with LEMS
Many SCLC LEMS patients are undiagnosed with LEMS and are being treated by oncologists Oncologists typically refer SCLC patients diagnosed with LEMS to neurologists or neuromuscular specialists ~ 1,000 new potential SCLC LEMS patients each year (includes diagnosed and undiagnosed) FIRDAPSE: Small Ce
Slide 10: FIRDAPSE: Expanding the Global Reach
FIRDAPSE: Expanding the Global Reach Global Expansion Initiatives Underway Canada Japan *DyDo, our partner in Japan, has submitted their NDA for FIRDAPSE (amifampridine) to the Pharmaceuticals and Medical Devices Agency (“PMDA”). Upon acceptance of the submission of the NDA for FIRDAPSE in Japan, ou
Slide 11: AGAMREE: Novel Corticosteroid Approved in the U.S.
AGAMREE: Novel Corticosteroid Approved in the U.S. for treatment in DMD patients ≥ 2yrs - October 2023 May increase ambulation duration and mobility, improving QoL Product launch expected in Q1 2024 Optimize neuromuscular franchise capabilities with minimal expansion Comprehensive Patient Assistance
Slide 12: AGAMREE: Addresses Need for Tolerable Steroid
AGAMREE: Addresses Need for Tolerable Steroid Currently treated DMD patients receive concomitant steroid treatment DMD patients treated with corticosteroids at some point DMD diagnosis rate; typically occurs at ages 2 - 5 years ~ 95% ˜ 90% ˜ 70% U.S. DMD patient prevalence: ˜ 11,000 to 13,000 Proven
Slide 13: Epilepsy Franchise
Epilepsy Franchise 13 @ Catalyst
Slide 14: Established, First-in-Class Commercial Epilepsy Asset FYCOMPA
Established, First-in-Class Commercial Epilepsy Asset FYCOMPA® (perampanel) CIII Synergistic Neurology Expansion Acquired U.S. rights in January 2023 Franchise teams fully engaged - May 2023 Franchise physician call points overlap - 45% Compelling product net revenue contribution Seek to expand into
Slide 15: FYCOMPA: Broad Spectrum Efficacy
FYCOMPA: Broad Spectrum Efficacy Only Non-Competitive AMPA Receptor Antagonist Simple once-a-day dosing Long half-life, relieving the anxiety of breakthrough seizures if a dose is missed >70% retention rate for adult patients Seizure-freedom rate is ˜ 72% when used adjunctively Patent exclusivity un
Slide 16: FYCOMPA: Significant Market Opportunity
FYCOMPA: Significant Market Opportunity Epilepsy - High Unmet Medical Need 1England MJ, Liverman CT, Schultz AM, Strawbridge LM, eds. Epilepsy Across the Spectrum: Promoting Health and Understanding. Washington, DC: National Academies Press (US); 2012. 2CDC Epilepsy Data and Statistics; Epilepsy Pre
Slide 17: Catalyst Pipeline
Catalyst Pipeline 17 @ Catalyst
Slide 18: *FIRDAPSE is currently approved in the U.S. for the treatment of LEMS in patients
*FIRDAPSE is currently approved in the U.S. for the treatment of LEMS in patients 6 years of age and older
Slide 19: Corporate Highlights
Corporate Highlights 19 @ Catalyst
Slide 20: Sustained Product Portfolio Growth
Sustained Product Portfolio Growth Demonstrated Commercial Execution 3Q 22 vs 3Q 23 Net Revenue Performance Q3 22 Q3 23 Q3 22 Q3 23 Q3 22 Q3 23
Slide 21: Q3 2023 Financial Highlights
Q3 2023 Financial Highlights FY 2023 Total Revenue of Between $390M - $395M * Non-GAAP net income excludes from the calculation of net income (i) the expense associated with non-cash stock-based compensation, (ii) non-cash depreciation expense, (iii) non-cash amortization of intangible assets expens
Slide 22: Underscores Successful Execution
Underscores Successful Execution (In $ Millions) FY Dec-19 FY Dec-20 FY Dec-21 Cash & Cash Equivalents 55.2 130.0 171.1 Firdapse 100.8 117.6 138.2 Revenue 101.6 118.3 140.7 Strong Financial Position (In Millions) Q3 23 Results Cash Position as of Sept 30, 2023 $121.0 Total Revenues for the three mon
Slide 23: Continued Drivers to Deliver Long-Term Value
Continued Drivers to Deliver Long-Term Value 2023 Accomplishments Anticipated 2024 Milestones Launched inaugural ESG report Continue to pursue synergistic rare CNS opportunities Appointed new CEO and CFO effective 2024 Expanded focus to SCLC patients comorbid with LEMS Pursuing global expansion of F
Slide 24: Strategic Growth Initiatives
Strategic Growth Initiatives Expand Commercial Footprint Invest in Portfolio Diversification Expand Portfolio in Rare & Orphan Diseases Explore commercial add-on assets both in the U.S. and globally Synergistic expertise to foster innovations Harness operational capabilities and industry expertise S
Slide 25: Market Cap as of Dec 28, 2023
NASDAQ: CPRX *Market Cap as of Dec 28, 2023
Slide 26: Sy ¥2C
Sy ¥2C 2-Catalyst Ye NASDAQ: CPRX
Catalyst Pharmaceuticals — Investor Presentation (January 2024) on 6ix